← Back to All US Stocks

Invivyd, Inc. (IVVD) Stock Fundamental Analysis & AI Rating 2026

IVVD Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001832038
Updated This Month • Analysis: Mar 29, 2026 • SEC Data: 2025-12-31
Combined AI Rating
SELL
78% Confidence
AGREEMENT
SELL
85% Conf
HOLD
72% Conf

📊 IVVD Key Takeaways

Revenue: $53.4M
Net Margin: -98.2%
Free Cash Flow: $-58.3M
Current Ratio: 7.24x
Debt/Equity: 0.00x
EPS: $-0.30
AI Rating: SELL with 85% confidence
Invivyd, Inc. (IVVD) receives a SELL rating with 78% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $53.4M, net profit margin of -98.2%, and return on equity (ROE) of -21.7%, Invivyd, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete IVVD stock analysis for 2026.

Is Invivyd, Inc. (IVVD) a Good Investment?

Claude

Invivyd is a pre-commercial or early-stage biopharmaceutical company with severe profitability challenges, burning $58.1M in operating cash flow annually despite 110.5% revenue growth. While the company maintains strong liquidity with $226.7M in cash and minimal debt, the current burn rate combined with negative 98.2% net margins and -109.1% free cash flow margin indicates the business model is not yet viable at scale.

ChatGPT

Invivyd shows strong top-line momentum, with revenue more than doubling year over year, and its balance sheet is unusually strong for a loss-making biotech, supported by $226.69M in cash and no meaningful debt. However, growth quality remains weak because operating losses still exceed revenue, net margin is deeply negative, and free cash flow burn remains substantial. The company has enough liquidity to keep executing, but fundamentals still depend on proving that revenue growth can translate into materially better margins and lower cash burn.

Why Buy Invivyd, Inc. Stock? IVVD Key Strengths

Claude
  • + Strong revenue growth of 110.5% YoY indicates market traction and demand
  • + Excellent liquidity position with $226.7M cash and 7.24x current ratio provides runway for operations
  • + Negligible debt burden (0.00x debt-to-equity) provides financial flexibility without leverage risk
ChatGPT
  • + Revenue grew 110.5% year over year, indicating meaningful commercial traction
  • + Cash and equivalents of $226.69M with no long-term debt provide strong financial flexibility
  • + Liquidity is very strong, with current and quick ratios above 7x

IVVD Stock Risks: Invivyd, Inc. Investment Risks

Claude
  • ! Massive cash burn of $58.1M annually in operating activities threatens sustainability despite large cash reserves
  • ! Severely negative profitability metrics (net margin -98.2%, operating margin -104%) indicate business is unprofitable at scale
  • ! At current burn rate, cash runway appears limited to approximately 3.9 years, requiring path to profitability within that window
  • ! 10 Form 4 insider filings in 90 days may signal insider concerns or management transitions
ChatGPT
  • ! Operating margin of -104.0% shows the business is still not economically self-sustaining
  • ! Free cash flow of -$58.29M indicates continued heavy cash burn despite revenue growth
  • ! Net margin of -98.2% suggests current growth has not yet converted into durable profitability

Key Metrics to Watch

Claude
  • * Operating cash burn rate - critical to track if burn is decelerating with growing revenue
  • * Gross margin achievement - need visibility on gross profitability to assess unit economics
  • * Revenue growth sustainability - monitor if 110% growth can be maintained and convert to profitability
  • * Cash burn runway and path to breakeven - essential for assessing going concern risks
ChatGPT
  • * Operating cash burn and free cash flow trend
  • * Operating margin improvement relative to revenue growth

Invivyd, Inc. (IVVD) Financial Metrics & Key Ratios

Revenue
$53.4M
Net Income
$-52.5M
EPS (Diluted)
$-0.30
Free Cash Flow
$-58.3M
Total Assets
$276.9M
Cash Position
$226.7M

💡 AI Analyst Insight

Strong liquidity with a 7.24x current ratio provides a solid financial cushion.

IVVD Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -104.0%
Net Margin -98.2%
ROE -21.7%
ROA -19.0%
FCF Margin -109.1%

IVVD vs Healthcare Sector: How Invivyd, Inc. Compares

How Invivyd, Inc. compares to Healthcare sector averages

Net Margin
IVVD -98.2%
vs
Sector Avg 12.0%
IVVD Sector
ROE
IVVD -21.7%
vs
Sector Avg 15.0%
IVVD Sector
Current Ratio
IVVD 7.2x
vs
Sector Avg 2.0x
IVVD Sector
Debt/Equity
IVVD 0.0x
vs
Sector Avg 0.6x
IVVD Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Invivyd, Inc. Stock Overvalued? IVVD Valuation Analysis 2026

Based on fundamental analysis, Invivyd, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-21.7%
Sector avg: 15%
Net Profit Margin
-98.2%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Invivyd, Inc. Balance Sheet: IVVD Debt, Cash & Liquidity

Current Ratio
7.24x
Quick Ratio
7.11x
Debt/Equity
0.00x
Debt/Assets
12.8%
Interest Coverage
N/A
Long-term Debt
N/A

IVVD Revenue & Earnings Growth: 5-Year Financial Trend

IVVD 5-year financial data: Year 2024: Revenue $25.4M, Net Income -$198.6M, EPS $-1.81. Year 2025: Revenue $53.4M, Net Income -$169.9M, EPS $-1.43.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Invivyd, Inc.'s revenue has grown significantly by 110% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.43 indicates the company is currently unprofitable.

IVVD Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-109.1%
Free cash flow / Revenue

IVVD Quarterly Earnings & Performance

Quarterly financial performance data for Invivyd, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $9.3M -$10.5M $-0.06
Q2 2025 $2.3M -$14.7M $-0.12
Q1 2025 N/A -$16.3M $-0.14
Q3 2024 N/A -$35.3M $-0.36
Q2 2024 N/A -$35.3M $-0.40

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Invivyd, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$58.1M
Cash generated from operations
Capital Expenditures
$155.0K
Investment in assets
Dividends
None
No dividend program

IVVD SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Invivyd, Inc. (CIK: 0001832038)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 8-K d147019d8k.htm View →
Apr 6, 2026 DEF 14A ivvd-20260406.htm View →
Mar 5, 2026 10-K ivvd-20251231.htm View →
Mar 5, 2026 8-K d118119d8k.htm View →
Feb 18, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about IVVD

What is the AI rating for IVVD?

Invivyd, Inc. (IVVD) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are IVVD's key strengths?

Claude: Strong revenue growth of 110.5% YoY indicates market traction and demand. Excellent liquidity position with $226.7M cash and 7.24x current ratio provides runway for operations. ChatGPT: Revenue grew 110.5% year over year, indicating meaningful commercial traction. Cash and equivalents of $226.69M with no long-term debt provide strong financial flexibility.

What are the risks of investing in IVVD?

Claude: Massive cash burn of $58.1M annually in operating activities threatens sustainability despite large cash reserves. Severely negative profitability metrics (net margin -98.2%, operating margin -104%) indicate business is unprofitable at scale. ChatGPT: Operating margin of -104.0% shows the business is still not economically self-sustaining. Free cash flow of -$58.29M indicates continued heavy cash burn despite revenue growth.

What is IVVD's revenue and growth?

Invivyd, Inc. reported revenue of $53.4M.

Does IVVD pay dividends?

Invivyd, Inc. does not currently pay dividends.

Where can I find IVVD SEC filings?

Official SEC filings for Invivyd, Inc. (CIK: 0001832038) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is IVVD's EPS?

Invivyd, Inc. has a diluted EPS of $-0.30.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is IVVD a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Invivyd, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is IVVD stock overvalued or undervalued?

Valuation metrics for IVVD: ROE of -21.7% (sector avg: 15%), net margin of -98.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy IVVD stock in 2026?

Our dual AI analysis gives Invivyd, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is IVVD's free cash flow?

Invivyd, Inc.'s operating cash flow is $-58.1M, with capital expenditures of $155.0K. FCF margin is -109.1%.

How does IVVD compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -98.2% (avg: 12%), ROE -21.7% (avg: 15%), current ratio 7.24 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 29, 2026 | Data as of: 2025-12-31 | Powered by Claude AI